IL262482A - New polypeptides - Google Patents

New polypeptides

Info

Publication number
IL262482A
IL262482A IL262482A IL26248218A IL262482A IL 262482 A IL262482 A IL 262482A IL 262482 A IL262482 A IL 262482A IL 26248218 A IL26248218 A IL 26248218A IL 262482 A IL262482 A IL 262482A
Authority
IL
Israel
Prior art keywords
novel polypeptides
polypeptides
novel
Prior art date
Application number
IL262482A
Other languages
English (en)
Hebrew (he)
Inventor
Eva Dahlen
Peter Ellmark
Christina Furebring
Per Norlen
Anna Sall
Laura Von Schantz
Niina Veitonmaki
Sara Fritzell
Jessica Petersson
Laura Varas
Original Assignee
Alligator Bioscience Ab
Eva Dahlen
Peter Ellmark
Christina Furebring
Per Norlen
Anna Sall
Laura Von Schantz
Niina Veitonmaki
Sara Fritzell
Jessica Petersson
Laura Varas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alligator Bioscience Ab, Eva Dahlen, Peter Ellmark, Christina Furebring, Per Norlen, Anna Sall, Laura Von Schantz, Niina Veitonmaki, Sara Fritzell, Jessica Petersson, Laura Varas filed Critical Alligator Bioscience Ab
Publication of IL262482A publication Critical patent/IL262482A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71Decreased effector function due to an Fc-modification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74Inducing cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75Agonist effect on antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
IL262482A 2016-04-22 2018-10-21 New polypeptides IL262482A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201607046 2016-04-22
PCT/EP2017/059656 WO2017182672A1 (fr) 2016-04-22 2017-04-24 Nouveaux polypeptides bispécifiques dirigés contre le cd137

Publications (1)

Publication Number Publication Date
IL262482A true IL262482A (en) 2018-12-31

Family

ID=58609424

Family Applications (1)

Application Number Title Priority Date Filing Date
IL262482A IL262482A (en) 2016-04-22 2018-10-21 New polypeptides

Country Status (14)

Country Link
US (2) US20190169308A1 (fr)
EP (1) EP3445788B1 (fr)
JP (2) JP2019523630A (fr)
KR (1) KR102426765B1 (fr)
CN (1) CN109195994A (fr)
AU (1) AU2017252233A1 (fr)
BR (1) BR112018071612A2 (fr)
CA (1) CA3021618A1 (fr)
DK (1) DK3445788T3 (fr)
ES (1) ES2910365T3 (fr)
IL (1) IL262482A (fr)
MX (1) MX2018012897A (fr)
RU (1) RU2018139339A (fr)
WO (1) WO2017182672A1 (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017271601A1 (en) 2016-05-27 2018-12-13 Abbvie Biotherapeutics Inc. Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
CN109311993B (zh) 2016-06-20 2022-12-20 F-星治疗有限公司 Lag-3结合元件
SG11201811064TA (en) 2016-06-20 2019-01-30 F Star Delta Ltd Binding molecules binding pd-l1 and lag-3
US11091557B2 (en) 2016-07-14 2021-08-17 Genmab A/S Methods of producing multispecific antibodies against CD40 and CD137
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
JP7305538B2 (ja) 2016-09-23 2023-07-10 メルス ナムローゼ フェンノートシャップ 細胞によって発現される生物活性を調節する結合分子
EP3619235A1 (fr) 2017-04-11 2020-03-11 Inhibrx, Inc. Constructions polypeptidiques multispécifiques comprenant une liaison cd3 contrainte et leurs méthodes d'utilisation
EP3609921A2 (fr) 2017-04-13 2020-02-19 Agenus Inc. Anticorps anti-cd137 et procédés d'utilisation correspondants
WO2019016402A1 (fr) 2017-07-20 2019-01-24 Aptevo Research And Development Llc Protéines de liaison à l'antigène se liant à 5t4 et 4-1bb, compositions et procédés associés
SG11202000198QA (en) 2017-08-04 2020-02-27 Genmab As Binding agents binding to pd-l1 and cd137 and use thereof
CA3082321A1 (fr) * 2017-11-13 2019-05-16 Crescendo Biologics Limited Anticorps a domaine unique qui se lient a cd137
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
CA3086098A1 (fr) 2017-12-19 2019-06-27 F-Star Beta Limited Sequences de liaison specifiques a pd-l1 inserees dans un domaine ch3
CN109970865B (zh) * 2017-12-28 2022-10-04 上海细胞治疗研究院 一种cd137双向激活共刺激分子受体及其用途
EP3765493A2 (fr) 2018-03-12 2021-01-20 Genmab A/S Anticorps
MX2020010444A (es) * 2018-04-04 2021-01-08 Bicycletx Ltd Complejos de péptidos bicíclicos en heterotándem.
WO2019232323A1 (fr) * 2018-05-31 2019-12-05 Board Of Regents, The University Of Texas System Anticorps bispécifiques et utilisation associées
WO2019234187A1 (fr) * 2018-06-06 2019-12-12 Leadartis, S.L. Complexes polypeptidiques trimériques et leurs utilisations
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201811450D0 (en) * 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811404D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811415D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
CA3113539A1 (fr) * 2018-10-10 2020-04-16 Zymeworks Inc. Constructions d'anticorps se liant a 4-1bb et antigenes associes a une tumeur et leurs utilisations
US20210340273A1 (en) * 2018-10-11 2021-11-04 Inhlbrx, inc. 5t4 single domain antibodies and therapeutic compositions thereof
CN112638950A (zh) * 2018-10-22 2021-04-09 上海一宸医药科技有限公司 一种双特异性抗体
US20220056136A1 (en) * 2018-11-30 2022-02-24 Abl Bio Inc. Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof
CN113677710A (zh) * 2018-12-17 2021-11-19 鳄鱼生物科学公司 多肽
WO2020127376A2 (fr) * 2018-12-17 2020-06-25 Alligator Bioscience Ab Nouveaux polypeptides
TWI793395B (zh) * 2019-01-25 2023-02-21 大陸商信達生物製藥(蘇州)有限公司 結合pd-l1和ox40的雙特異性抗體
GB201905100D0 (en) * 2019-04-10 2019-05-22 Antibody Innovation Ltd Polypeptides and methods of use
KR20220007098A (ko) 2019-05-09 2022-01-18 바이사이클티엑스 리미티드 Ox40에 특이적인 이환식 펩티드 리간드
WO2021020846A1 (fr) * 2019-07-26 2021-02-04 Abl Bio Inc. Anticorps bispécifique anti-her2/anti-4-1bb et son utilisation
AU2020320349A1 (en) * 2019-07-26 2022-02-17 Abl Bio Inc. Anti-EGFR/anti-4-1BB bispecific antibody and use thereof
TW202110485A (zh) 2019-07-30 2021-03-16 英商拜西可泰克斯有限公司 異質雙環肽複合物
CN112592404B (zh) * 2019-09-20 2023-07-25 上海交通大学医学院 抗体活性改造及其筛选方法
JP2022551607A (ja) 2019-10-03 2022-12-12 バイスクルテクス・リミテッド ヘテロタンデム二環式ペプチド複合体
EP3816185A1 (fr) 2019-11-04 2021-05-05 Numab Therapeutics AG Anticorps multi-spécifique contra pd-l1 et antigène associé à une tumeur
WO2021101346A1 (fr) * 2019-11-21 2021-05-27 Dong-A St Co., Ltd. Anticorps bispécifiques anti-ror1/anti-4-1bb et leurs utilisations
US20230048361A1 (en) 2019-12-31 2023-02-16 Kahr Medical Ltd. Methods of culturing t cells and uses of same
WO2021137231A1 (fr) 2019-12-31 2021-07-08 Kahr Medical Ltd. Procédés de culture de lymphocytes t avec un polypeptide de fusion 4-1bbl et leurs utilisations
KR20220124718A (ko) 2020-01-07 2022-09-14 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 암 치료를 위한 개선된 인간 메틸 티오아데노신/아데노신 고갈 효소 변이체
CN115151573A (zh) * 2020-02-28 2022-10-04 上海复宏汉霖生物技术股份有限公司 抗cd137构建体、多特异性抗体及其用途
EP4136122A4 (fr) * 2020-04-15 2024-05-15 Zymeworks Bc Inc Constructions d'anticorps se liant à 4-1bb et récepteurs alpha de folate et leurs utilisations
KR20230042524A (ko) * 2020-08-07 2023-03-28 주식회사 유틸렉스 항-her2 / 항-4-1bb 이중특이적 항체 및 이의 용도
CA3173151A1 (fr) * 2020-11-03 2022-05-12 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Anticorps anti-cd28 bispecifiques et bivalents, co-stimulants, restreints a une cellule cible
US20240084025A1 (en) * 2021-01-25 2024-03-14 Yuhan Corporation Methods for purifying an anti-4-1bb/anti-her2 bispecific antibody
CA3228414A1 (fr) * 2021-09-02 2023-03-09 Anthony DANIYAN Anticorps anti-cd33 et leurs utilisations
WO2023061421A1 (fr) * 2021-10-12 2023-04-20 Concept To Medicine Biotech Co., Ltd. Anticorps anti-4-1bb à domaine unique
WO2023174521A1 (fr) * 2022-03-15 2023-09-21 Genmab A/S Agents de liaison se liant à epcam et cd137
WO2024051752A1 (fr) * 2022-09-06 2024-03-14 I-Mab Biopharma Co., Ltd. Constructions multispécifiques et leurs utilisations
WO2024061364A1 (fr) * 2022-09-22 2024-03-28 成都盛世君联生物技术有限公司 Nanocorps anti-4-1bb, sa préparation et son utilisation
WO2024085166A1 (fr) * 2022-10-19 2024-04-25 アステラス製薬株式会社 Utilisation d'un anticorps bispécifique anti-cldn4-anti-cd137 associé à un inhibiteur de signal pd-1 pour le traitement du cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
CA2192782C (fr) 1995-12-15 2008-10-14 Nobuyuki Takechi Production de microsphere
EP2161286A1 (fr) * 1999-11-18 2010-03-10 Oxford Biomedica (UK) Limited Anticorps
EP1975182A1 (fr) * 2000-02-01 2008-10-01 PanGenetics B.V. Molécules d'activation des APC se liant au CD40
GT200500255A (es) 2004-09-10 2006-04-10 Anticuerpos anti-5ta humanizados y conjugados anticuerpo anti-5ta/calicheamicina
CN103347898B (zh) * 2011-01-10 2017-12-05 Ct大西洋有限公司 包括与肿瘤相关抗原结合抗体的联合治疗
EP3590965A1 (fr) 2011-03-29 2020-01-08 Roche Glycart AG Variants de fc d'anticorps
JP2014533929A (ja) * 2011-09-23 2014-12-18 アムゲン リサーチ (ミュンヘン) ゲーエムベーハー 5t4およびcd3に対する二重特異的結合性分子
WO2014116846A2 (fr) * 2013-01-23 2014-07-31 Abbvie, Inc. Procédés et compositions pour moduler une réponse immunitaire
TWI726842B (zh) * 2014-04-07 2021-05-11 日商中外製藥股份有限公司 免疫活化抗原結合分子
US20150307620A1 (en) * 2014-04-16 2015-10-29 University Of Connecticut Linked immunotherapeutic agonists that costimulate multiple pathways
CN105233291A (zh) * 2014-07-09 2016-01-13 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
CA2969888A1 (fr) * 2015-01-08 2016-07-14 Biontech Ag Agents agonistes se liant aux recepteurs du tnf
BR112017015136A2 (pt) * 2015-01-14 2018-01-30 Compass Therapeutics Llc polipeptídeo de construto de ligação ao antígeno imunomodulador multiespecífico, construto de ligação ao antígeno imunomodulador multiespecífico, conjugado, composição farmacêutica, método para tratar um indivíduo com câncer, método para inibir ou reduzir o crescimento de câncer, composição, célula, método de fazer um polipeptídeo de construto de ligação ao antígeno imunomodulador multiespecífico, vetor ou conjunto de vetores e kit
MX2017014699A (es) * 2015-05-21 2018-04-11 Alligator Bioscience Ab Polipeptidos novedosos.
AU2018224094A1 (en) * 2017-02-24 2019-09-19 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof

Also Published As

Publication number Publication date
US20190169308A1 (en) 2019-06-06
WO2017182672A1 (fr) 2017-10-26
CN109195994A (zh) 2019-01-11
CA3021618A1 (fr) 2017-10-26
KR102426765B1 (ko) 2022-07-29
JP2019523630A (ja) 2019-08-29
US20220213213A1 (en) 2022-07-07
RU2018139339A (ru) 2020-05-22
EP3445788B1 (fr) 2022-01-19
ES2910365T3 (es) 2022-05-12
JP2022058338A (ja) 2022-04-12
DK3445788T3 (en) 2022-04-11
RU2018139339A3 (fr) 2020-09-28
KR20180135454A (ko) 2018-12-20
BR112018071612A2 (pt) 2019-02-19
AU2017252233A1 (en) 2018-11-15
EP3445788A1 (fr) 2019-02-27
MX2018012897A (es) 2019-01-17

Similar Documents

Publication Publication Date Title
IL262482A (en) New polypeptides
IL255767A (en) New polypeptides
ZA201802261B (en) Polypeptides
HK1250041A1 (zh) 多肽
GB201611530D0 (en) Novel polypeptides
HK1254601A1 (zh) 新型肽
ZA201704366B (en) Il-17a-binding polypeptides
HK1250040A1 (zh) 多肽
GB201608197D0 (en) Novel proteins
ZA201701348B (en) New polypeptides
GB201607534D0 (en) Peptides
GB201707139D0 (en) Polypeptides
GB201619652D0 (en) Novel polypeptides
GB201604468D0 (en) Peptides
GB201607535D0 (en) Peptides
IL246533A0 (en) new proteins
GB201717958D0 (en) Novel polypeptides
GB201706915D0 (en) Novel polypeptides
GB201515245D0 (en) Novel polypeptides
GB201620022D0 (en) Novel peptide
GB201622143D0 (en) Modification of polypeptides
GB201612665D0 (en) Peptides
GB201608820D0 (en) Peptides
GB201603582D0 (en) Peptides
GB201419237D0 (en) Novel polypeptides